Cargando…
Drug-induced liver injury in COVID-19 patients during hospitalization
Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, an...
Autores principales: | Chen, Ying, Shi, Cai, Zhan, Haiyan, Yang, Boning, Liu, Jun, Rong, Peipei, Luo, Yi, Yang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018522/ https://www.ncbi.nlm.nih.gov/pubmed/36930097 http://dx.doi.org/10.1097/MD.0000000000033294 |
Ejemplares similares
-
Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients
por: Zhang, Shuxiao, et al.
Publicado: (2023) -
Network pharmacology integrated with molecular docking technology to reveal the potential mechanism of Shuganfang against drug-induced liver injury
por: Wang, Ying, et al.
Publicado: (2023) -
A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers
por: Li, Zhen, et al.
Publicado: (2020) -
Reversible severe fatty liver induced by capecitabine: A case report
por: Jiang, Yiyan, et al.
Publicado: (2017) -
Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report
por: Abramavicius, Silvijus, et al.
Publicado: (2017)